<DOC>
	<DOCNO>NCT01643759</DOCNO>
	<brief_summary>This single center , open label , randomize , parallel group single dose pharmacokinetic ( PK ) study .</brief_summary>
	<brief_title>Norspan Transdermal Patches Study Osteoarthritis Patients</brief_title>
	<detailed_description>After 7-day screening period , Eligible Patients randomize 1 3 treatment group , begin treatment BTDS 5mg , 10mg,20mg 7 days.Venous blood collect 0 , 6 , 12 , 24 , 36 , 48 , 60 , 72 , 96,120 , 144,168,169,170,171,172,174,180,192,216 , 240 h postdose respectively.Plasma concentration buprenorphine norbuprenorphine analyze determine follow pharmacokinetic parameter : AUC0-t , AUC0-inf , Cmax , Tmax , t½ .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Patients volunteer participation study . Male female patient diagnosis osteoarthritis , age 20 60 year . Body weight ≥ 50kg , BMI range ≧ 18.5 , ﹤ 30 . Having result within follow range judge eligible study participation investigator : Systolic blood pressure ( supine ) , 90140 mm Hg , Diastolic blood pressure ( supine ) , 6090 mm Hg , Armpit body temperature , 35.037.5 degree Celsius . Agreed use medication ( except vitamin mineral supplement ) course study . Have smoke chew tobacco least 45 day prior dose study drug , agree use tobacco product study . Females childbearing potential must negative serum pregnancy test screen visit checkin . Subjects take opioid analgesic formulation excess 7 day within 3 month Visit 1 . Subjects take CYP3A4 inhibitor inducer within last 1 month prior screen visit . Subjects take medication include OTC ( except vitamin and/or mineral supplement ) within 7 day prior first dose trial product . Patients current chronic disease ( ) , past history high possibility relapse , addition musculoskeletal pain , require frequent analgesic therapy . Subjects clinically unstable respiratory disease , dysfunction biliary tract , thyroid disease , adrenal cortical insufficiency , prostatic hypertrophy require intervention renal artery stenosis . Subject past history malignant neoplasm . Subjects clinically unstable , active symptomatic heart disease . Subjects psychiatric disorder , uncontrolled seizure convulsive disorder . Subjects medical surgical condition might interfere transdermal absorption , distribution , metabolism , excretion drug . History frequent nausea emesis regardless etiology . Subjects current past history substance alcohol abuse , subject give positive result drug abuse test Screening Period . Subjects schedule therapy within study period might effect study assessment . Subjects value &gt; 2 time upper limit normal AST ALT total bilirubin Screening Period severe impair liver function . Subjects serum creatinine &gt; 2 mg/dL Screening Period severe impair renal function . Subjects serum potassium &lt; 3.5 mEq/L Screening Period . Subjects positive result antihuman immunodeficiency virus antibody , hepatitis B surface antigen , hepatitis C virus antibody qualitative syphilis test . Donated 400 mL blood blood product within 3 month prior start study , donate 200 mL blood blood product within 1 month prior start study . Subjects history supersensitivity study drug . Subjects participate clinical research study within 1 month study entry . Subjects participate previously BTDS study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>osteoarthritis disorder</keyword>
</DOC>